


The new RIDA[®]GENE Parainfluenza real-time PCR is a sensitive and specific assay for the detection and differentiation of HPIV1, HPIV3 and HPIV2/4

Objectives

Human Parainfluenza viruses (HPIV) cause both upper respiratory infections and lower respiratory infections. Mainly, HPIV1, 2 and 3, and sporadically HPIV4 account for the major community-acquired respiratory pathogens worldwide. There is a clear relationship between the different HPIV serogroups and presentation of respiratory disease, as well as the seasonal appearance of each of the four HPIV types (Figure 1).



Methods

The RIDA[®]GENE Parainfluenza real-time PCR assay simultaneously detects and differentiates HPIV1, HPIV3 and HPIV2/4 using fluorogenic target-specific hydrolysis probes. In a retrospective study, a total of 118 positive and negative respiratory samples (nose/throat swabs; pharyngeal lavage) were extracted

using the MagNAPure 96 (Roche). Extracted nucleic acids were analysed with the RIDA[®]GENE Parainfluenza real-time PCR assav on the LightCycler[®] 480II (Roche). Results were compared to a standard reference in-house real-time PCR assay (Figure 2).

Epidemics of HPIV1 and 2 mostly occur

biannually in fall whereas HPIV3 epidemics in

North America and Europe occur yearly in

spring and summer.¹ Clinical symptoms are,

dependent on the different serogroup, croup,

bronchiolitis, pneumonia and tracheobronchi-

tis.² Similar symptoms occur in other respira-


differential diagnosis by real-time PCR is an

tory tract infections, therefore a specific

essential tool for detection of HPIV.

Art. No. PG5805

Picture 1: RIDA[®]GENE Parainfluenza



Results

Overall, 118 clinical samples were tested, of which 64 were nose and throat swabs and 54 was pharyngeal lavage material. 8 samples (6.8%) were positive for HPIV1 and 9 samples (7.6 %) were HPIV3-positive using the RIDA®GENE Parainfluenza real-time PCR assay (Figure 3, Table 1).

101 samples negative for either HPIV serogroup were found with the RIDA[®]GENE Parainfluenza real-time PCR assay (Table 1). These results concur with the results obtained with the reference in-house real-time PCR assay, indicating a positive, negative and

overall agreement of 100 %, respectively (Table 2).




Figure 3: Distribution of Parainfluenza subtypes in % found by RIDA®GENE Parainfluenza

Table 1: In-house real-time PCR vs. RIDA®GENE Parainfluenza real-time PCR


		In-house real-time PCR		
		+	-	Total
RIDA [®] GENE Parainfluenza	+	17	0	17
	-	0	101	101
	Total	17	101	118

Table 2: Clinical performance of the RIDA®GENE Parainfluenza real-time PCR assay



Negative agreement: 100 %

Overall agreement: 100 %



R-Biopharm AG • An der neuen Bergstraße 17, 64297 Darmstadt, Germany • Phone: +49 (0) 61 51 - 81 02-0, Fax: +49 (0) 61 51 - 81 02-40 • E-mail: info@r-biopharm.de • www.r-biopharm.com







A. Hiergeist[†], S. Stender[‡], L. Kastl[‡], A. Simons[‡] [†] microBIOMix GmbH, Regensburg, Germany * R-Biopharm AG, Darmstadt, Germany

Berman S. Epidemiology of acute respiratory infections in children of deveioning countries. Rev. Infect. Dis. 1991, 13:454-462.

Henrickson KJ. Parainfluenza viruses. Clin. Microbiol. Reviews. 2003, 16(2): 242-263. Hall CB. Respiratory Syncitial Virus and parainfluenza virus. N Engl J Med. 2001, 344(25):

Conclusion

The RIDA[®]GENE Parainfluenza real-time PCR assay shows good correlation with an established in-house real-time PCR method. It is a highly sensitive and specific assay for the simultaneous detection and differentiation of HPIV1, HPIV3 and HPIV2/4, Results are available in less than 2 hours. An included Internal Control RNA (ICR) detects PCR inhibition, monitors reagent integrity and confirms that nucleic acid extraction was sufficient and hence ensures reliable results.